# Dobutamine

Drug · id `cardio:dobutamine` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Dobutamine hydrochloride

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Acute care and long-term living  

## In plain language

Dobutamine is a medicine given into a vein. A US label for dobutamine in 5% dextrose injection lists it, when treatment by injection is needed, for short-term inotropic support, meaning support for a weakly contracting heart, in patients with cardiac decompensation due to depressed contractility. The label names two causes: organic heart disease and cardiac surgical procedures. The label says "Experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions." It adds that neither dobutamine nor any other cyclic-AMP-dependent inotrope "has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure." MeSH also notes its use during dobutamine stress echocardiography, a heart test.

## Technical summary

RxNorm ingredient 3616; UNII 0WR771DJXV is the UNII of the salt, dobutamine hydrochloride, that the label gives, so it is a broad match; MeSH descriptor D004280 (Dobutamine). US drug-label class: beta-Adrenergic Agonist (established pharmacologic class, RxClass). The MeSH scope note describes a catecholamine derivative with specificity for beta-1 adrenergic receptors. The label read is the Baxter Healthcare label for dobutamine hydrochloride in 5% dextrose, application NDA020255, effective 2023-09-08 in openFDA; the vial products under other applications were not read. The indication names cardiac decompensation due to depressed contractility, not heart failure by name. This page records the label indication and the class only: no trial result and no dose is given. The parent class page (inotropes and vasopressors) is not written yet, so the page has no parent link.

## Claims, with the population each applies to

## Context: Patients for whom the US dobutamine in dextrose injection label lists inotropic support: cardiac decompensation due to depressed contractility

Recipient: Recipient not specified; Population: Patients with cardiac decompensation due to depressed contractility from organic heart disease or from cardiac surgical procedures; the indication sentence does not name an age group.; Care setting: Intravenous (parenteral) therapy, as the indications section describes; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the indication sentence; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement); the label says controlled-trial experience does not extend beyond 48 hours

### The US label of dobutamine hydrochloride in 5% dextrose injection (Baxter Healthcare, NDA020255; version dated 8 September 2023 in openFDA) lists the medicine, when parenteral therapy is necessary, for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility, from organic heart disease or from cardiac surgical procedures. The label says "Experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions." It adds that neither dobutamine nor any other cyclic-AMP-dependent inotrope "has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure." It describes the medicine as a direct-acting inotropic agent whose main action is stimulation of the beta-receptors of the heart.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients with cardiac decompensation due to depressed contractility from organic heart disease or from cardiac surgical procedures; the indication sentence does not name an age group.; Care setting: Intravenous (parenteral) therapy, as the indications section describes; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the indication sentence; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement); the label says controlled-trial experience does not extend beyond 48 hours
- Limitations: This claim records what one label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded. The indication names cardiac decompensation due to depressed contractility, not heart failure by name. Only the indications section and the first sentence of the pharmacology section were read; contraindications, warnings, doses and adverse reactions were not recorded. The same active substance is also sold as a vial product under other applications, which were not read. openFDA says its data are unvalidated and not to be relied on for decisions about medical care.
- Last checked: 2026-11-08
- Sources:
  1. Supports: openFDA drug label record: Dobutamine Hydrochloride in 5% Dextrose Injection (Baxter, NDA020255) (Label, edition openFDA drug label record, label effective 20230908, dataset last updated 2026-11-06.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b17b98b-e06d-42ed-925f-69aa2699dead>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-08T20:38:19Z. Source state: Current. Version fingerprint: ef860ea206236a678237592374a3093a5dbc978ebb897c416743b35200e8719b.
     How it applies: Quoted at this locator.
  2. Supports: openFDA drug label record: Dobutamine Hydrochloride in 5% Dextrose Injection (Baxter, NDA020255) (Label, edition openFDA drug label record, label effective 20230908, dataset last updated 2026-11-06.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b17b98b-e06d-42ed-925f-69aa2699dead>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-08T20:38:19Z. Source state: Current. Version fingerprint: ef860ea206236a678237592374a3093a5dbc978ebb897c416743b35200e8719b.
     How it applies: Quoted at this locator.
  3. Supports: openFDA drug label record: Dobutamine Hydrochloride in 5% Dextrose Injection (Baxter, NDA020255) (Label, edition openFDA drug label record, label effective 20230908, dataset last updated 2026-11-06.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b17b98b-e06d-42ed-925f-69aa2699dead>
     Locator: results\[0\].openfda.brand\_name\[0\]. Retrieved 2026-11-08T20:38:19Z. Source state: Current. Version fingerprint: ef860ea206236a678237592374a3093a5dbc978ebb897c416743b35200e8719b.
     How it applies: Quoted at this locator.
  4. Supports: openFDA drug label record: Dobutamine Hydrochloride in 5% Dextrose Injection (Baxter, NDA020255) (Label, edition openFDA drug label record, label effective 20230908, dataset last updated 2026-11-06.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b17b98b-e06d-42ed-925f-69aa2699dead>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 sentence 1, fragment 1 of 2. Retrieved 2026-11-08T20:38:19Z. Source state: Current. Version fingerprint: ef860ea206236a678237592374a3093a5dbc978ebb897c416743b35200e8719b.
     How it applies: Quoted at this locator.
  5. Supports: openFDA drug label record: Dobutamine Hydrochloride in 5% Dextrose Injection (Baxter, NDA020255) (Label, edition openFDA drug label record, label effective 20230908, dataset last updated 2026-11-06.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b17b98b-e06d-42ed-925f-69aa2699dead>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 sentence 1, fragment 2 of 2. Retrieved 2026-11-08T20:38:19Z. Source state: Current. Version fingerprint: ef860ea206236a678237592374a3093a5dbc978ebb897c416743b35200e8719b.
     How it applies: Quoted at this locator.
  6. Supports: openFDA drug label record: Dobutamine Hydrochloride in 5% Dextrose Injection (Baxter, NDA020255) (Label, edition openFDA drug label record, label effective 20230908, dataset last updated 2026-11-06.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b17b98b-e06d-42ed-925f-69aa2699dead>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 sentence 2. Retrieved 2026-11-08T20:38:19Z. Source state: Current. Version fingerprint: ef860ea206236a678237592374a3093a5dbc978ebb897c416743b35200e8719b.
     How it applies: Quoted at this locator.
  7. Supports: openFDA drug label record: Dobutamine Hydrochloride in 5% Dextrose Injection (Baxter, NDA020255) (Label, edition openFDA drug label record, label effective 20230908, dataset last updated 2026-11-06.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b17b98b-e06d-42ed-925f-69aa2699dead>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 sentence 3, part. Retrieved 2026-11-08T20:38:19Z. Source state: Current. Version fingerprint: ef860ea206236a678237592374a3093a5dbc978ebb897c416743b35200e8719b.
     How it applies: Quoted at this locator.
  8. Supports: openFDA drug label record: Dobutamine Hydrochloride in 5% Dextrose Injection (Baxter, NDA020255) (Label, edition openFDA drug label record, label effective 20230908, dataset last updated 2026-11-06.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b17b98b-e06d-42ed-925f-69aa2699dead>
     Locator: results\[0\].clinical\_pharmacology\[0\], 1. Retrieved 2026-11-08T20:38:19Z. Source state: Current. Version fingerprint: ef860ea206236a678237592374a3093a5dbc978ebb897c416743b35200e8719b.
     How it applies: Quoted at this locator.

## Connected pages

- The US label lists short-term inotropic support in cardiac decompensation due to depressed contractility: Heart failure (`cardio:heart-failure`) [a claim, not a settled fact; see claim `cardio:claim-fda-dobutamine-label-indications` and its context]
- Filed under this front: Medicines (`cardio:front-medicines`)
- The US label calls dobutamine a direct-acting inotropic agent: Inotropes and vasopressors (`cardio:inotropes-and-vasopressors`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 4 registry products
- 4 registry trials

## Provenance

Content hash: 72a2ac856ecd5b9e2ff764852970b12f67dff38d05e861cd42efa75ab1d780b5
Last substantive edit: 2026-11-08
Evidence last checked: 2026-11-08
